Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Gayan S. Jayawickrama"'
Publikováno v:
International Journal of Molecular Sciences, Vol 17, Iss 6, p 946 (2016)
Kynurenine aminotransferase isozymes (KATs 1–4) are members of the pyridoxal-5’-phosphate (PLP)-dependent enzyme family, which catalyse the permanent conversion of l-kynurenine (l-KYN) to kynurenic acid (KYNA), a known neuroactive agent. As KATs
Externí odkaz:
https://doaj.org/article/2cbbd65008894983b389b280c291751c
Publikováno v:
Molecules, Vol 21, Iss 7, p 856 (2016)
Abnormal levels of kynurenic acid (KYNA) in the human brain are believed to be connected to several central nervous system (CNS) diseases, therefore compounds which affect the production of this crucial metabolite are of interest in CNS drug developm
Externí odkaz:
https://doaj.org/article/38f51e7a20c7405fa8f0fd024c3838de
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0196404 (2018)
The mammalian kynurenine aminotransferase (KAT) enzymes are a family of related isoforms that are pyridoxal 5'-phosphate-dependent, responsible for the irreversible transamination of kynurenine to kynurenic acid. Kynurenic acid is implicated in human
Externí odkaz:
https://doaj.org/article/b0d5c3e3183f4e44858ae8b1bc46ecb0
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
Scientific Reports
Scientific Reports
The kynurenine aminotransferase (KAT) enzymes are pyridoxal 5′-phosphate-dependent homodimers that catalyse the irreversible transamination of kynurenine into kynurenic acid (KYNA) in the tryptophan metabolic pathway. Kynurenic acid is implicated i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d2d0fb4faab4f399d19bb6a178ef088
http://link.springer.com/article/10.1038/s41598-017-17979-7
http://link.springer.com/article/10.1038/s41598-017-17979-7
Publikováno v:
Medicinal Chemistry Research. 26:2514-2519
NS-1502 is a reversible inhibitor of human kynurenine aminotransferase-2 (hKAT-2), which is implicated in a number of central nervous system disorders. Although direct inhibition of KAT isozymes has been reported as an approach to manage neurodegener
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bda49ef8f92448040b8c6e79b0b21a1
https://doi.org/10.1007/s00044-017-1950-6
https://doi.org/10.1007/s00044-017-1950-6
Publikováno v:
SLAS discovery : advancing life sciences RD. 23(6)
Kynurenine aminotransferase-II (KAT-II) is a pyridoxal 5'-phosphate (PLP)-dependent enzyme that acts in the tryptophan metabolic pathway by catalyzing the transamination of kynurenine into kynurenic acid (KYNA). It is one of four isoforms in the KAT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d14d3e970972423947595d11eade954
https://pubmed.ncbi.nlm.nih.gov/29537924
https://pubmed.ncbi.nlm.nih.gov/29537924
DS_DISC764620 – Supplemental material for Fragment Screening of Human Kynurenine Aminotransferase-II
Supplemental material, DS_DISC764620 for Fragment Screening of Human Kynurenine Aminotransferase-II by Gayan S. Jayawickrama, Alireza Nematollahi, Guanchen Sun, W. Bret Church in SLAS Discovery
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::072bef2baf4717dd36db83ca248e7fff
Publikováno v:
Molecules; Volume 21; Issue 7; Pages: 856
Molecules
Molecules, Vol 21, Iss 7, p 856 (2016)
Molecules
Molecules, Vol 21, Iss 7, p 856 (2016)
Abnormal levels of kynurenic acid (KYNA) in the human brain are believed to be connected to several central nervous system (CNS) diseases, therefore compounds which affect the production of this crucial metabolite are of interest in CNS drug developm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8832a2f4fd48a96175bb6b3d6be58d77
Autor:
Naveed A. Nadvi, Alireza Nematollahi, W. Bret Church, Guanchen Sun, Mark D. Gorrell, Richard R. Sadig, Jane R. Hanrahan, Gayan S. Jayawickrama
Publikováno v:
Current medicinal chemistry. 22(24)
Schizophrenia is a complex neuropsychiatric disorder with limited treatment options and highly debilitating symptoms, leading to poor personal, social, and occupational outcomes for an afflicted individual. Our current understanding of schizophrenia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::245c0443e61cc722a06fe5942f4f2f7a
https://pubmed.ncbi.nlm.nih.gov/26051411
https://pubmed.ncbi.nlm.nih.gov/26051411